Skip to main content
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1985 Jul 15;133(2):111–112.

Relation of HTLV-III seropositivity and lymphadenopathy.

E Jeffries, W J Boyko, B Willoughby, P D Constance, B Wiggs, M O'Shaughnessy, F R Sharp
PMCID: PMC1346021  PMID: 2988732

Abstract

Testing for antibody to human T-lymphotropic retrovirus (HTLV-III) was carried out in five groups of homosexual men: 250 without lymphadenopathy (control group), 37 with slight or nonpersistent lymph node enlargement (intermediate group), 141 with persistent generalized lymphadenopathy, 32 with persistent generalized lymphadenopathy who underwent biopsy and 11 in whom acquired immune deficiency syndrome (AIDS) was diagnosed. The rates of HTLV-III seropositivity in the five groups were 18%, 32%, 61%, 94% and 91% respectively.

Full text

PDF
111

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barré-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet-Brun F., Rouzioux C. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871. doi: 10.1126/science.6189183. [DOI] [PubMed] [Google Scholar]
  2. Bayer H., Bienzle U., Schneider J., Hunsmann G. HTLV-III antibody frequency and severity of lymphadenopathy. Lancet. 1984 Dec 8;2(8415):1347–1347. doi: 10.1016/s0140-6736(84)90862-6. [DOI] [PubMed] [Google Scholar]
  3. Boyko W. J., Schechter M. T., Jeffries E., Douglas B., Maynard M., O'Shaughnessy M. The Vancouver Lymphadenopathy-AIDS Study: 3. Relation of HTLV-III seropositivity, immune status and lymphadenopathy. Can Med Assoc J. 1985 Jul 1;133(1):28–32. [PMC free article] [PubMed] [Google Scholar]
  4. Gallo R. C., Salahuddin S. Z., Popovic M., Shearer G. M., Kaplan M., Haynes B. F., Palker T. J., Redfield R., Oleske J., Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May 4;224(4648):500–503. doi: 10.1126/science.6200936. [DOI] [PubMed] [Google Scholar]
  5. Levy J. A., Hoffman A. D., Kramer S. M., Landis J. A., Shimabukuro J. M., Oshiro L. S. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science. 1984 Aug 24;225(4664):840–842. doi: 10.1126/science.6206563. [DOI] [PubMed] [Google Scholar]
  6. Metroka C. E., Cunningham-Rundles S., Pollack M. S., Sonnabend J. A., Davis J. M., Gordon B., Fernandez R. D., Mouradian J. Generalized lymphadenopathy in homosexual men. Ann Intern Med. 1983 Nov;99(5):585–591. doi: 10.7326/0003-4819-99-5-585. [DOI] [PubMed] [Google Scholar]
  7. Sarngadharan M. G., Popovic M., Bruch L., Schüpbach J., Gallo R. C. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science. 1984 May 4;224(4648):506–508. doi: 10.1126/science.6324345. [DOI] [PubMed] [Google Scholar]
  8. Schechter M. T., Boyko W. J., Jeffries E., Willoughby B., Nitz R., Constance P. The Vancouver Lymphadenopathy-AIDS Study: 1. Persistent generalized lymphadenopathy. Can Med Assoc J. 1985 Jun 1;132(11):1273–1279. [PMC free article] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES